Daedamab High Velocity Antibody Discovery
Webinar Recording Daedamab High Velocity Antibody DiscoveryCONTACT Access the webinar recording Thanks for your interest in our recent Daedamab webinar recording. Please fill out the form, and we will send you a link to the webinar with a passcode shortly. Our approach generates a diverse set of antibody candidates in as little as 2-3 months […]
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
Boston, MA, January 9th, 2025 – Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-GxTM antibody technology platform with no annual access fee or development milestones. […]
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
Boston, MA, January 7th, 2025 – Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target. In return, […]
Discovering Antibodies in Months
Access the webinar recording Thanks for your interest in our recent antibody discovery webinar, Discovering Antibodies in Months: New Advances in HT-SPR, Single-Cell BCR-Seq and RNA-Seq. Alloy Head of Global Bioanalytics Dr. Lucy Liu presented on our workflow that improve the speed and quality of the antibody discovery process. Please fill out your contact information, and […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Targeting GPCRs With DeepImmune™
AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms
Access the webinar recording Thanks for your interest in our recent AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording. Our approach Initiating antibody […]
Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Access the webinar recording Thanks for your interest in our recent Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording. Our approach Plasma cells are an important source of antibodies and are important […]
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
Tokyo & Boston, November 20, 2024 – Alloy Therapeutics Inc. ( “Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) […]
